MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...

– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available ...

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure ...

Jasper Therapeutics (JSPR) announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of ...

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...